Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations

Transplantation

Volumn 88, Issue 1, 2009, Pages 62-68

  Tory, Rita ^a   Sachs Barrable, Kristina ^a   Goshko, Caylee Britt ^a   Hill, John S ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dyslipidemia; Lipoprotein lipase; Renal transplant; Tacrolimus; Triglyceride

Indexed keywords

BASILIXIMAB; CEFAZOLIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COTRIMOXAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; REGULATOR PROTEIN; TACROLIMUS; TRIACYLGLYCEROL; CETP PROTEIN, HUMAN; HEPATIC LIPASE, HUMAN; IMMUNOSUPPRESSIVE AGENT; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOWN REGULATION; DRUG COMBINATION; DRUG MONITORING; MIDDLE AGED; TIME;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DOWN-REGULATION; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPASE; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS; TRIGLYCERIDES;

EID: 67651012060     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181aa7d04     Document Type: Article

References (36)

1. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
2. Montanaro D, Gropuzzo M, Tulissi P, et al. Cardiovascular disease after renal transplantation. G Ital Nefrol 2004; 21(suppl 26): S53.
3. Del Castillo D, Cruzado JM, Manel Diaz J, et al. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrol Dial Transplant 2004; 19(suppl 3): iii67.
4. Fellstrom B, Holdaas H, Jardine AG, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in Renal Transplantation (ALERT) Trail. Transplantation 2005; 79: 205.
5. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study. Am J Transplant 2005; 5: 2929.
6. Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 2001; 72(6 suppl): S13.
7. Sigfusson G, Fricker FJ, Bernstein D, et al. Long-term survivors of pediatric heart transplantation: A multicenter report of sixty-eight children who have survived longer than five years. J Pediatr 1997; 130: 862.
8. Penson MG, Winter WE, Fricker FJ, et al. Tacrolimus-based tripledrug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999; 18: 707.
9. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. ClinNephrol 1998; 49: 356.
10. White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: The Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005; 24: 798.
11. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
12. Perrea DN, Moulakakis KG, Poulakou MV, et al. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008; 40: 521.
13. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: A single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146.
14. Greenstein SM, Sun S, Calderon TM, et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res 2000; 91: 123.
15. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk. Drugs 2004; 64: 2047.
16. Wasan KM, Donnachie EM, Seccombe DW, et al. Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts. J Pharm Sci 2002; 91: 2520.
17. Derfler K, Hayde M, Heinz G, et al. Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporine A. Kidney Int 1991; 40: 720.
18. Mizuta K, Kobayashi E, Uchida H, et al. Influence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model. Comparative study with cyclosporine. Transpl Int 1999; 12: 316.
19. Cofan F, Cofan M, Campos B, et al. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Transplant Proc 2005; 37: 3791.
20. Tory R, Sachs-Barrable K, Hill JS, et al. Cyclosporine A and rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int J Pharm 2008; 358: 219.
21. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992; 287(Pt 2): 337.
22. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrinol Metab 2002; 13: 174.
23. Qiu X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007; 14: 106.
24. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417.
25. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470.
26. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350.
27. Hill JS, Yang D, Nikazy J, et al. Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding. J Biol Chem 1998; 273: 30979.
28. Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta 1993; 216: 113.
29. Tornvall P, Olivecrona G, Karpe F, et al. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1086.
30. Miyashita Y, Shirai K, Itoh Y, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 2002; 56: 181.
31. Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. Bio Drugs 2001; 15: 261.
32. Morales JM, Dominguez-Gil B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens 2005; 23: 1609.
33. Steinmuller TM, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - A randomized trial. Transplantation 1994; 58: 669.
34. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000; 294: 778.
35. Schaefer HM, Kizilisik AT, Feurer I, et al. Short-term results under three different immunosuppressive regimens at one center. Transplant Proc 2006; 38: 3466.
36. Alssema M, Schindhelm RK, Dekker JM, et al. Determinants of postprandial triglyceride and glucose responses after two consecutive fatrich or carbohydrate-rich meals in normoglycemic women and in women with type 2 diabetes mellitus: The Hoorn Prandial Study. Metabolism 2008; 57: 1262.